Subutex and Suboxone both contain buprenorphine, the same partial opioid agonist, but only Suboxone adds naloxone, and that single difference shapes when each one gets prescribed. Here at Healthy Life Recovery, we know that being handed a prescription you don't fully understand is its own kind of stress.
This guide covers what separates Subutex and Suboxone, how pregnancy and liver function change the calculation, and how induction timing works now that fentanyl is in most of the supply. If you're weighing options for yourself or someone you love, our medication-assisted treatment program pairs buprenorphine management with therapy and monitoring in San Diego.
Both medications are buprenorphine. Suboxone adds naloxone, which does almost nothing when the film dissolves under your tongue but triggers withdrawal if the product is injected. Buprenorphine alone still has a role in pregnancy, in serious liver impairment, and in some low-dose starts. The formulation is your prescriber's call, and it can change as your situation does.
How Subutex and Suboxone Work
Both medications deliver buprenorphine, a partial mu-opioid agonist. It binds tightly to opioid receptors and quiets withdrawal and cravings without producing the full effect of heroin, oxycodone, or fentanyl, which is why it anchors most opiate addiction treatment plans. Because the response plateaus rather than climbing with every dose increase, buprenorphine behaves differently from a full agonist at higher doses.
SAMHSA's TIP 63 guidance describes this plateau directly: buprenorphine "has less potential to cause respiratory depression, given its ceiling effect," and once it reaches a moderate dose, "its effects no longer increase if the dose is increased." That ceiling is a meaningful safety feature, though it isn't absolute. Fatal overdose remains possible in three situations:
What the Naloxone in Suboxone Actually Does
Naloxone is an opioid antagonist. It's in Suboxone to make the product less appealing to inject, not to protect against overdose and not to alter the medication's day-to-day effects.
The FDA label for Suboxone sublingual film is specific on this point. Naloxone "had no clinically significant effect when administered by the sublingual route, although blood levels of the drug were measurable." Injected, the picture reverses: the label states that Suboxone "is likely to produce withdrawal signs and symptoms if misused parenterally by individuals dependent on full opioid agonists."
The deterrent isn't airtight, and it's worth being honest about that. The same label acknowledges that some people, particularly those with lower physical dependence or dependence primarily on buprenorphine itself, still misuse the combination intravenously or intranasally.
Quick Definitions
Head-to-Head Comparison
The practical differences come down to five things: what's in each product, which forms are still manufactured, how they're dosed, what happens when liver function is impaired, and how each one fits into a longer outpatient treatment plan.
Two clarifications are worth making, because both get repeated inaccurately across the web:
When Clinicians Choose Buprenorphine Alone
A handful of situations point toward the monoproduct. In each case the reasoning is specific and documented in the chart, not a matter of preference.
Severe or Moderate Liver Impairment
This is the clearest case, and the mechanism is usually described backwards. The issue is naloxone exposure, not liver damage. Impaired liver function cuts naloxone clearance far more than buprenorphine's, so naloxone accumulates, rising more than tenfold in severe impairment per SAMHSA's TIP 63.
FDA labeling follows: combination products are not recommended in severe hepatic impairment and may not be appropriate in moderate impairment, since excess naloxone "may result in an increased risk of precipitated withdrawal." TIP 63 suggests halving the usual monoproduct doses.
Pregnancy
Guidance here is genuinely in motion, so treat any confident single answer with suspicion.
ACOG's Committee Opinion 711, reaffirmed in 2026, notes the monoproduct "has been recommended during pregnancy to avoid any potential prenatal exposure to naloxone." It adds that recent studies of the combination product "found no adverse effects," and expects its use to expand.
ASAM's committee considers the combination safe and effective here. SAMHSA's TIP 63 still favors the monoproduct, noting its expert panel couldn't agree. This is a decision for an obstetric clinician and a prescriber together, with integrated dual-diagnosis and medical care coordinated around it.
Documented Naloxone Intolerance
True allergy or severe intolerance to naloxone requires avoiding naloxone-containing products. This is uncommon, and it should be documented clearly rather than assumed from a bad induction experience, which is far more often a timing issue.
Some Low-Dose Initiations
Clinicians sometimes use the monoproduct briefly during a low-dose start, where dosing precision at very small amounts matters more than the injection deterrent. It's a temporary tactical choice, not a long-term plan.
Fentanyl and the Timing of a First Dose
Fentanyl is lipophilic, meaning it accumulates in body tissue and releases back into circulation for longer than heroin or short-acting prescription opioids. That's why standard induction timing built around older drug supplies doesn't always translate cleanly, and why fentanyl addiction treatment often starts differently than it would have a decade ago.
The research on how often this actually causes problems is mixed, and both numbers deserve to be on the table. A 2024 cohort study in JAMA Network Open of 226 hospitalized and emergency department patients using fentanyl found precipitated withdrawal in 12% after buprenorphine initiation.
A larger multisite emergency department trial published in 2023, enrolling 1,200 patients, reported precipitated withdrawal in 0.76%. The risk is real and worth planning around. It isn't the near-certainty some accounts suggest.
Low-Dose Initiation
ASAM's 2023 clinical considerations use the term low-dose buprenorphine with opioid continuation rather than "microdosing," noting that the longer phrase is the clinically accurate one. The approach starts buprenorphine at very small doses, often 0.25 mg to 1 mg sublingually, while the full agonist continues, then builds buprenorphine up over roughly three to 10 days before the full agonist stops.
ASAM is measured about the evidence. Case reports cover a combined total of more than 250 patients, and the document states plainly that "no available data exist to recommend a specific dosing schedule."
Its framework suggests considering low-dose initiation when the COWS score is below 8, and standard initiation when COWS is 8 or higher with at least one objective sign of withdrawal. SAMHSA's TIP 63 predates the practice and doesn't describe it, so this shouldn't be presented as a SAMHSA recommendation.
If you're navigating fentanyl withdrawal specifically, the sequencing question matters more than the product question.
What the Timing Guidance Actually Says
Wait times vary by source, and blending them into one number does readers a disservice. Here's what each body says for short-acting opioids.
For methadone or another long-acting opioid, the interval stretches considerably. ASAM points to 24 to 72 hours, and TIP 63 notes that waiting 36 hours or more reduces risk further.
Switching Between the Two
Moving between buprenorphine and buprenorphine/naloxone is usually a straightforward substitution. The buprenorphine component converts at the same total daily dose, so 8 mg/2 mg of Suboxone becomes 8 mg of buprenorphine, with the schedule unchanged.
A few practical points make these transitions go smoothly:
For anyone stepping into treatment from medically supervised detox, the medication decision is usually made alongside the level-of-care decision rather than separately.
Side Effects and What to Expect
Because both products deliver the same active medication, their side-effect profiles are close to identical when taken as directed.
Stopping Buprenorphine
Withdrawal after discontinuing buprenorphine is generally milder than withdrawal from short-acting opioids, though that doesn't make it comfortable. The FDA label describes a syndrome that "is typically milder than seen with full agonists and may be delayed in onset," and directs prescribers to taper gradually rather than stop abruptly.
No authoritative body publishes a day-by-day buprenorphine taper timeline, so treat any precise schedule you find online with skepticism. If you're curious how opioid withdrawal generally unfolds, our opioid withdrawal timeline covers the broader pattern, and the lingering symptoms some people notice for months afterward are described in our guide to post-acute withdrawal syndrome.
One thing worth naming plainly: continuing medication alongside counseling and follow-up is associated with better outcomes than stopping abruptly, according to NIDA's review of medications for opioid use disorder. If tapering is on your mind, it's a conversation to have with your prescriber rather than a decision to make alone.
Other Buprenorphine Formulations
Sublingual products aren't the only option, and some older articles list products that no longer exist.
If you've wondered whether Suboxone gets you high, that question has a clearer answer than most people expect.
Access and Coverage
Generic buprenorphine and generic buprenorphine/naloxone are typically easier to fill than brand-name products, since payers tend to place FDA-equivalent generics on preferred tiers.
Coverage specifics vary too much by plan and state for anyone to predict from the outside, so the fastest path is to ask directly. Useful questions for your insurer:
If a prior authorization is needed, prescribers generally submit a dated diagnostic note, current opioid use history, prior treatment attempts and outcomes, and a treatment plan with monitoring and follow-up. When the monoproduct is the request, the clinical reason belongs in the documentation explicitly.
Our team can verify your benefits at no cost before you commit to anything.
Common Misconceptions
Not when the film or tablet is used as directed. Sublingual naloxone has no clinically significant effect per FDA labeling. It becomes active if the product is injected.
Almost never. It usually means buprenorphine was started before enough of the previous opioid had cleared. Same medication, different timing, different result.
Physical dependence and addiction aren't the same thing. SAMHSA's guidance supports buprenorphine treatment for opioid use disorder as a way of reducing cravings, illicit use, and overdose risk.
The brand was discontinued commercially in 2011, and the FDA explicitly determined it was not withdrawn for safety or effectiveness reasons.
Severe liver injury isn't a common effect in people with normal liver function. The label notes rare hepatotoxicity reports, which is why prescribers monitor liver tests in people with existing liver disease.
What Comprehensive MAT Looks Like at Healthy Life Recovery
Medication works best as one piece of a larger plan. SAMHSA guidance recommends pairing medication with psychosocial care, and that's how we structure treatment at our Pacific Beach location. Our care model brings together:
We're an outpatient program with medically supervised detox, not a residential or inpatient facility. For clients whose depression persists alongside recovery, we also offer TMS, which is FDA-cleared for major depressive disorder and OCD, and qEEG assessment to inform psychiatric planning.
When to Call Your Clinic
Reach out to your prescriber or care team promptly if you notice:
Talk with your current prescriber before changing medications so the handoff is safe. If you're in San Diego and looking for local care, you can contact our admissions team at (844) 410-6443 to talk through options.
Frequently Asked Questions
No. Milligram for milligram of buprenorphine, they deliver the same active medication. An 8 mg buprenorphine tablet and an 8 mg/2 mg Suboxone film provide the same buprenorphine dose. The naloxone doesn't add or subtract potency when taken under the tongue.
Not under the brand name. Its manufacturer stopped marketing Subutex in 2011. Generic buprenorphine sublingual tablets are still produced by multiple manufacturers and are what prescribers use when the monoproduct is clinically indicated.
That pattern usually points to precipitated withdrawal, which happens when buprenorphine displaces another opioid from receptors before enough of it has cleared. It's a timing issue rather than a reaction to naloxone. If it happened to you, tell your prescriber before the next attempt so the approach can be adjusted.
There's no fixed duration. Some people take it for months, others for years, and there's no clinical requirement to stop by a certain point. Stopping abruptly is associated with higher relapse risk, so any taper is worth planning gradually with your prescriber.
Most plans cover medication for opioid use disorder, though formulary tiers, prior authorization rules, and network requirements differ. We verify your benefits for free so you know where you stand before starting.
ACOG recommends buprenorphine as a treatment for opioid use disorder in pregnancy. Whether that's the monoproduct or the combination product is an individualized decision, since ACOG notes recent studies of the combination found no adverse effects while SAMHSA guidance still leans toward the monoproduct. This belongs in a conversation with both an obstetric clinician and a prescriber.
Yes, and the naloxone inside Suboxone doesn't replace it. Rescue naloxone is a separate product for reversing an overdose. Keep it accessible and make sure household members know where it is and how to use it.
Photo ID, your insurance card, a current medication list, and any recent prescribing or treatment records. A rough timeline of your opioid use, including when you last used, helps the clinical team plan induction safely. You can contact our admissions team with questions beforehand.
Usually, yes. The buprenorphine dose converts one to one, so the total daily amount and schedule stay the same. Your prescriber will document the reason for the change and monitor you for a day or two afterward.
It can be, with adjustments. Combination products aren't recommended in severe hepatic impairment because naloxone clearance drops sharply. The monoproduct is generally preferred there, often at reduced starting and titration doses, with liver testing to guide the plan.
Written by the Healthy Life Recovery clinical team and reviewed by Dr. John Allen, MD. Last reviewed July 2026. Clinical statements reflect current FDA prescribing information, SAMHSA TIP 63, ASAM practice guidance, and ACOG Committee Opinion 711.
§ Disclaimer. This article is for informational and educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about your specific situation. If you or someone you know is in crisis, call or text 988 (Suicide & Crisis Lifeline). Healthy Life Recovery provides outpatient treatment, medically supervised detox, and partner sober living, not inpatient or residential care. Individual experiences vary and no specific outcome is guaranteed.
